Suzhou Basecare Medical Corp. Ltd. Class H (HK:2170)
:2170
Want to see HK:2170 full AI Analyst Report?
2170 Stock Chart & Stats
HK$1.97
HK$0.20(8.26%)
At close: 4:00 PM EST
HK$1.97
HK$0.20(8.26%)
Day’s Range― - ―
52-Week RangeHK$1.78 - HK$4.36
Previous CloseN/A
Volume107.50K
Average Volume (3M)121.73K
Market Cap
HK$319.28M
Enterprise ValueHK$251.53M
Total Cash (Recent Filing)HK$545.48M
Total Debt (Recent Filing)HK$342.23M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding82,713,840
10 Day Avg. Volume98,950
30 Day Avg. Volume121,733
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)0.49
Price to Sales (P/S)2.01
P/FCF Ratio-1.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.23
Revenue Forecast (FY)HK$412.00M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Revenue ModelBasecare's core sales mix includes single-use consumables and procedure-linked items for IVF labs, creating a recurring revenue stream tied to patient volume. This installed-base recurring demand supports predictability and resilience in revenues over a multi-month horizon, reducing reliance on one-off device sales.
Solid Product-level Gross Margins (~48%)A near-50% gross margin indicates strong product-level economics for devices and consumables, giving the company room to absorb SG&A or invest in R&D. If revenue stabilizes, these margins provide a credible path to improved operating leverage and eventual positive contribution margin over several quarters.
Moderate Leverage And Sizable Equity BufferDebt-to-equity around 0.37 and large equity provide a meaningful balance-sheet cushion to absorb ongoing losses and fund near-term operations. This capital structure reduces immediate refinancing pressure and gives management time to execute operational fixes or raise capital on less dilutive terms over the coming months.
Bears Say
Persistent Operating Cash Burn And Negative Free Cash FlowSustained negative operating cash flow and large negative FCF mean the business consumes cash rather than generating it, creating ongoing funding needs. Over 2-6 months this raises the risk of additional debt, equity issuance, or cutbacks to operations, constraining strategic flexibility and growth investments.
Very Large Operating Losses And Deeply Negative Net MarginExtremely negative EBIT and net margins show the company is far from break-even; persistent losses depress ROE (about -23%) and erode capital. Without sustained margin improvement or cost restructuring, the firm will struggle to convert healthy gross margins into net profitability, limiting long-term viability.
Recent Sharp Revenue Decline (-17.6% In 2025)A material YoY revenue drop after prior growth raises concern about demand sustainability, competitive pressure, or pricing/volume declines. Reduced procedure-linked sales weaken the recurring consumables base and make it harder to leverage fixed costs, prolonging the path to break-even over several quarters.
Suzhou Basecare Medical Corp. Ltd. Class H News
2170 FAQ
What was Suzhou Basecare Medical Corp. Ltd. Class H’s price range in the past 12 months?
Suzhou Basecare Medical Corp. Ltd. Class H lowest stock price was HK$1.78 and its highest was HK$4.36 in the past 12 months.
What is Suzhou Basecare Medical Corp. Ltd. Class H’s market cap?
Suzhou Basecare Medical Corp. Ltd. Class H’s market cap is HK$319.28M.
When is Suzhou Basecare Medical Corp. Ltd. Class H’s upcoming earnings report date?
Suzhou Basecare Medical Corp. Ltd. Class H’s upcoming earnings report date is Aug 31, 2026 which is in 124 days.
How were Suzhou Basecare Medical Corp. Ltd. Class H’s earnings last quarter?
Suzhou Basecare Medical Corp. Ltd. Class H released its earnings results on Mar 30, 2026. The company reported -HK$0.408 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.408.
Is Suzhou Basecare Medical Corp. Ltd. Class H overvalued?
According to Wall Street analysts Suzhou Basecare Medical Corp. Ltd. Class H’s price is currently Overvalued.
Does Suzhou Basecare Medical Corp. Ltd. Class H pay dividends?
Suzhou Basecare Medical Corp. Ltd. Class H does not currently pay dividends.
What is Suzhou Basecare Medical Corp. Ltd. Class H’s EPS estimate?
Suzhou Basecare Medical Corp. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Suzhou Basecare Medical Corp. Ltd. Class H have?
Suzhou Basecare Medical Corp. Ltd. Class H has 82,713,840 shares outstanding.
What happened to Suzhou Basecare Medical Corp. Ltd. Class H’s price movement after its last earnings report?
Suzhou Basecare Medical Corp. Ltd. Class H reported an EPS of -HK$0.408 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.5%.
Which hedge fund is a major shareholder of Suzhou Basecare Medical Corp. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2170
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Suzhou Basecare Medical Corp. Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.08%
12-Months-Change
Fundamentals
Return on Equity
-16.83%
Trailing 12-Months
Asset Growth
-9.31%
Trailing 12-Months
Company Description
Suzhou Basecare Medical Corp. Ltd. Class H
Suzhou Basecare Medical Corporation Limited, an investment holding company, engages in the research, development, manufacture, and provision of genetic testing solutions for assisted reproduction and sale of genetic testing devices and instruments in the People's Republic of China. The company offers genetic test kit products, which include pre-implantation genetic test kits, such as PGT-A to detect aneuploidy; PGT-M to detect single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage. It also provides prenatal test kit products comprising CNV kits; postnatal test kit products consist of WES kits; and devices and instruments, including liquid nitrogen storage dewar, cryostorage system, automated workstation, sperm quality analyzer, and NGS sequencer. The company also engages in the research, development, manufacture, and sale of medical devices and instruments. In addition, it provides marketing services; and engages in the research and development of software for medical devices and instruments. The company serves hospitals and reproductive clinics. Suzhou Basecare Medical Corporation Limited was incorporated in 2010 and is headquartered in Suzhou, China.
Technical Analysis
Peijia Medical Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
Broncus Holding Corp.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Venus Medtech (Hangzhou), Inc. Class H
―